<DOC>
	<DOCNO>NCT00422292</DOCNO>
	<brief_summary>This modify single-blind , randomize , parallel-group , comparative , multicenter study test Menactra vaccine toddler . Primary Objectives : - To evaluate antibody response induce Measles , Mumps , Rubella , Varicella ( MMRV ) vaccine administer alone concomitantly Menactra vaccine . - To evaluate antibody response induce Pneumococcal Conjugated Vaccine ( PCV ) administer alone concomitantly Menactra vaccine . Observational Objectives : Safety - To describe safety profile throughout course study Day 0 6 month last study vaccination [ ] ) subject study group . Immunogenicity : - To describe antibody response meningococcal serogroups A , C , Y , W-135 , 30 day first second Menactra vaccine administration subset subject first study group .</brief_summary>
	<brief_title>Immunogenicity Safety Pediatric Vaccines When Administered With Menactra® Healthy Toddlers</brief_title>
	<detailed_description>No meningococcal vaccine presently license population age &lt; 2 year US , establish effectiveness quadrivalent polysaccharide conjugate vaccine invasive meningococcal disease child age &lt; 2 year would address important , currently unmet public health need . At enrollment , 9-month old subject randomly assign study group vaccinate . A second vaccination administer 12 month age . Subjects provide one blood sample trial . Twelve-month old subject also vaccinate routine pediatric vaccine provide one blood sample 30 day vaccination control group</detailed_description>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Measles</mesh_term>
	<mesh_term>Rubella</mesh_term>
	<mesh_term>Chickenpox</mesh_term>
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Meningitis , Meningococcal</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Inclusion Criteria : Healthy , determine medical history physical examination Aged 9 month ( 249 291 day ) Groups 1 , 2 , 3 age 12 month ( 365 386 day ) Group 4 time enrollment The parent legal guardian sign dated Institutional Review Board ( IRB ) approve informed consent form . Exclusion Criteria : Serious acute chronic disease ( e.g. , cardiac , renal , metabolic , rheumatologic , psychiatric , hematologic , autoimmune disorder , diabetes , atopic condition , congenital defect , convulsion , encephalopathy , blood dyscrasia , leukemia , lymphomas type , malignant neoplasm affect bone marrow lymphatic system , acute untreated tuberculosis ) could interfere trial conduct completion Known suspect impairment immunologic function Acute medical illness within last 72 hour temperature ≥ 100.4ºF ( ≥38.0ºC ) time enrollment . History document invasive meningococcal disease previous meningococcal vaccination . Known human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C seropositivity report parent legal guardian Received either immune globulin blood product within last 3 month , receive injected oral corticosteroid , immunomodulator therapy within 6 week study vaccine . Individuals taper dose schedule oral steroid last &lt; 7 day individual ( e.g. , asthmatic ) short schedule oral steroid last 3 4 day may include trial long receive one course within last two week prior enrollment . Topical steroid include exclusion criterion . Anticipated receive oral inject antibiotic therapy within 72 hour prior blood draw . Topical antibiotic antibiotic drop include exclusion criterion . Suspected known hypersensitivity vaccine component history lifethreatening reaction study vaccine vaccine contain substance . For ProQuad vaccine recipient , include hypersensitivity gelatin history anaphylactic reaction neomycin . Thrombocytopenia bleed disorder contraindicate intramuscular ( IM ) vaccination . Parent legal guardian unable unwilling comply study procedure Participation another interventional clinical trial 30 day precede enrollment plan participation another clinical trial involve investigation drug , vaccine , medical procedure , medical device subject 's trial period . Diagnosed condition , , opinion investigator , would pose health risk subject interfere evaluation vaccine Received vaccine 30day period prior receipt study vaccine , schedule receive vaccination influenza vaccination hyposensitization therapy 30day period receipt study vaccine . Hyposensitization therapy influenza vaccination may receive two week two week receive study vaccine . Subjects receive fourth dose Pneumococcal conjugate vaccine ( PCV ) Haemophilus influenzae type b ( Hib ) vaccine first dose Measles , mumps , rubella , varicella ( MMRV ) vaccine enrollment schedule receive vaccine outside studyspecified visit . Personal family history GuillainBarré Syndrome ( GBS ) History seizure , include febrile seizure , neurologic disorder Known hypersensitivity dry natural rubber latex .</criteria>
	<gender>All</gender>
	<minimum_age>9 Months</minimum_age>
	<maximum_age>12 Months</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Menactra vaccine</keyword>
	<keyword>Meningococcal meningitis</keyword>
	<keyword>Measles</keyword>
	<keyword>Mumps</keyword>
	<keyword>Rubella</keyword>
	<keyword>Varicella vaccine</keyword>
	<keyword>Haemophilus influenzae type b</keyword>
	<keyword>Pneumococcal conjugate vaccine</keyword>
</DOC>